IGEA to expands its market with Acalis group
The international healthcare group Acalis intends to distribute IGEA’s tests kits and dietary supplements along with Meditalia’s polymeric based med-tech products.
Hoofddorp, the Netherlands, January 27, 2020. IGEA Pharma N.V. (SIX: IGPH) today announced the signature of a memorandum of understanding with Acalis, an internationally active healthcare group with over 40 hospitals and support facilities.
As a result of this understanding, Acalis intends to exclusively distribute in Middle East and some European and South American countries, including Belgium, Chile, Colombia, Uruguay and Peru, IGEA’s Alz1 kit and Alz1 Tab supplement for the measurement and control of an Alzheimer’s disease related risk factor. The parties intend also to add additional countries. The signature of the final agreements between IGEA and Acalis is expected on or before April 2020.
IGEA and Acalis will also agree on the distribution of the polymeric based med-tech products and devices of the spin-off of MeditaliaS.r.l, on which IGEA, as previously disclosed, will get ownership within March 2020.
Acalis, created by Bart Vanderschrick in 2006, is an international healthcare group, whose goal is to maximize the standards of comfort in care around the world, building the new generation of care environments. Acalis and AcalisCare are brands that today represent a seal of quality in the field of elderly care, home care, rehabilitation and post-hospital support. With more than 40 hospitals for long-term care, the management of over 3,000 beds and more than 2,600 employees, Acalis has become a global partner for people in need of care in long-term care facilities, with rehabilitation centers, hospitals and home care. As such, Acalis is one of the most global private home care and assistance providers in Europe, Latin America and Middle East, in particular Saudi Arabia and Turkey, and is expanding in Asia and North America.
“Acalis and Acaliscare carry out activities strictly related to our products – said Vincenzo Moccia – CEO of IGEA – which will allow us to speed up the distribution of our products in new promising markets”.
“As the founder of Acalis and AcalisCare, I am very happy to sign this agreement with IGEA as their products are perfectly fitting in the markets and the clients we serve” said Bart Vanderschrick, founder and CEO of Acalis. “We as Acalis and AcalisCare are feeling very positive about the IGEA products”.
About IGEA
IGEA is a group focused on health-tech products and devices operating on the US market. IGEA commercializeAlz1, an at-home lab testing kit to measure non ceruloplasmin bound copper (generally defined as “free” copper) in the bloodstream and Alz1Tab, a natural dietary supplement
designed to reduce and control heavy metal contents in the bloodstream. “Free” copper is a risk factor associated with Alzheimer’s and diabetes type II. Monitoring and normalizing “free” copper can contribute to reduce the risk of Alzheimer’s and diabetes type II respectively.
IGEA is listed on the SIX Swiss Exchange under the ticker IGPH and is headquartered in Hoofddorp, the Netherlands.
For further information, please visit the IGEA website at igeapharma.nl/
IGEA Pharma N.V. Investor Relations: igeapharma.nl/investors-relations/
Contact
Vincenzo Moccia, CEO
Tel +31 23 568 94 94/ +39 340 583 09 33
moccia@igearesearch.com
Patrick Pozzorini, CFO
Tel +31 23 568 94 94/ +41 79 314 41 43
pozzorini@igearesearch.com
IGEA Pharma N.V.
Siriusdreef 17, 2123 WT Hoofddorp, the Netherlands
ir@igearesearch.com
Legal Disclaimer
This document constitutes neither an offer to buy nor to subscribe securities and neither this document nor any part of it should form the basis of any investment decision in IGEA.
The information contained in this press release has been carefully prepared. However, IGEA bears and assumes no liability of whatever kind for the correctness and completeness of the information provided herein. IGEA does not assume an obligation of whatever kind to update or correct information contained in this press release whether as a result of new information, future events or for other reasons.
This publication may contain specific forward-looking statements and assessments or intentions concerning IGEA and its business. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of IGEA and those explicitly or implicitly presumed in these statements. Against the background of these uncertainties, readers should not rely on forward-looking statements. IGEA assumes no responsibility to update forward-looking statements or to adapt them to future events or developments, except as may be required by law.